Butobarbital

Not to be confused with Butabarbital.
Butobarbital
Clinical data
Trade namesSoneryl
AHFS/Drugs.comInternational Drug Names
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • AU: S8 (Controlled drug)
  • CA: Schedule IV
  • DE: Anlage II (Authorized trade only, not prescriptible)
Pharmacokinetic data
MetabolismLiver
ExcretionKidney
Identifiers
IUPAC name
  • 5-Butyl-5-ethyl-1,3-diazinane-2,4,6-trione
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.928
Chemical and physical data
FormulaC10H16N2O3
Molar mass212.249 g·mol−1
3D model (JSmol)
SMILES
  • O=C1NC(=O)NC(=O)C1(CCCC)CC
InChI
  • InChI=1S/C10H16N2O3/c1-3-5-6-10(4-2)7(13)11-9(15)12-8(10)14/h3-6H2,1-2H3,(H2,11,12,13,14,15) checkY
  • Key:STDBAQMTJLUMFW-UHFFFAOYSA-N checkY
  (verify)

Butobarbital, also called butobarbitone or butethal, Soneryl, and Neonal,[1] is a hypnotic drug which is a barbiturate derivative.[2] It was developed by Poulenc Brothers (now part of Sanofi) in 1921.[3]

References

  1. ^ International Drug Names
  2. ^ Nordegren T (2002). "Butobarbital". The A-Z encyclopedia of alcohol and drug abuse. Parkland, Fla.: Brown Walker Press. p. 144. ISBN 978-1-58112-404-0.
  3. ^ DE 481129, "Verfahren zur Herstellung von n-Butylaethylbarbitursaeure", published 3 February 1922, issued 14 August 1929, assigned to ETS Poulenc Freres. 


This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.